179 related articles for article (PubMed ID: 8549418)
1. Activity of quinolones against gram-positive cocci: clinical features.
Giamarellou H
Drugs; 1995; 49 Suppl 2():58-66. PubMed ID: 8549418
[TBL] [Abstract][Full Text] [Related]
2. The fluoroquinolones as treatment for infections caused by gram-positive bacteria.
Cruciani M; Bassetti D
J Antimicrob Chemother; 1994 Mar; 33(3):403-17. PubMed ID: 8040107
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of temafloxacin against gram-positive cocci including methicillin-resistant Staphylococcus aureus.
Fuchs PC
Am J Med; 1991 Dec; 91(6A):15S-18S. PubMed ID: 1662886
[TBL] [Abstract][Full Text] [Related]
4. [The history of the development and changes of quinolone antibacterial agents].
Takahashi H; Hayakawa I; Akimoto T
Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
[TBL] [Abstract][Full Text] [Related]
5. Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Reddy AK; Garg P; Alam MR; Gopinathan U; Sharma S; Krishnaiah S
Eye (Lond); 2010 Jan; 24(1):170-4. PubMed ID: 19229279
[TBL] [Abstract][Full Text] [Related]
6. Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.
Jones RN; Pfaller MA; Stilwell M;
Diagn Microbiol Infect Dis; 2001 Feb; 39(2):133-5. PubMed ID: 11248528
[TBL] [Abstract][Full Text] [Related]
7. New antimicrobial agents as therapy for resistant gram-positive cocci.
Lentino JR; Narita M; Yu VL
Eur J Clin Microbiol Infect Dis; 2008 Jan; 27(1):3-15. PubMed ID: 17899228
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.
Wickman PA; Black JA; Moland ES; Thomson KS
Antimicrob Agents Chemother; 2006 Jun; 50(6):2255-7. PubMed ID: 16723599
[TBL] [Abstract][Full Text] [Related]
9. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
Rolston KV; Yadegarynia D; Kontoyiannis DP; Raad II; Ho DH
Int J Infect Dis; 2006 May; 10(3):223-30. PubMed ID: 16439177
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.
Korten V; Tomayko JF; Murray BE
Antimicrob Agents Chemother; 1994 Mar; 38(3):611-5. PubMed ID: 8203863
[TBL] [Abstract][Full Text] [Related]
11. The role of fluoroquinolones in the management of skin, soft tissue, and bone infections.
Fong IW
Clin Invest Med; 1989 Feb; 12(1):44-9. PubMed ID: 2646054
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci.
Miranda AG; Wanger AR; Singh KV; Murray BE
Antimicrob Agents Chemother; 1992 Jun; 36(6):1325-8. PubMed ID: 1329621
[TBL] [Abstract][Full Text] [Related]
13. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin and sparfloxacin: new quinolone antibiotics.
Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
[TBL] [Abstract][Full Text] [Related]
15. Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
Thys JP; Jacobs F; Byl B
Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):304-15. PubMed ID: 1864291
[TBL] [Abstract][Full Text] [Related]
16. In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci.
López Y; Tato M; Espinal P; Garcia-Alonso F; Gargallo-Viola D; Cantón R; Vila J
J Antimicrob Chemother; 2015 Jan; 70(1):57-61. PubMed ID: 25261416
[TBL] [Abstract][Full Text] [Related]
17. Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.
Maschmeyer G
Drugs; 1993; 45 Suppl 3():73-80. PubMed ID: 7689455
[TBL] [Abstract][Full Text] [Related]
18. A prospective, randomized study of pefloxacin versus teicoplanin in the treatment of gram-positive coccal infections in cancer patients: early termination due to emergence of resistance to fluoroquinolones.
Aoun M; Van der Auwera P; Varthalitis I; Bourguignon AM; Janssen M; Daneau D; Meunier F
Support Care Cancer; 1994 May; 2(3):191-6. PubMed ID: 8032706
[TBL] [Abstract][Full Text] [Related]
19. Newer quinolones in the treatment of continuous ambulatory peritoneal dialysis (CAPD) related infections.
Nikolaidis P
Perit Dial Int; 1990; 10(2):127-33. PubMed ID: 2085597
[TBL] [Abstract][Full Text] [Related]
20. Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):408-13. PubMed ID: 9699393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
